NASDAQ · IOVA
Healthcare · Biotechnology
$13.31
Up+$1.31 (+9.84%)
Updated Oct 10, 2026, 1:42 AM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · IOVA
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
IOVA closed at $13.31 after 20 trading sessions, up 54.77% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $12.645 | $13.395 | $12.62 | $13.31 | 14.82M |
| Oct 7, 2026 | $12.515 | $13.148 | $12.31 | $12.915 | 14.53M |
| Oct 6, 2026 | $14.21 | $14.21 | $12.92 | $12.96 | 18.95M |
| Oct 5, 2026 | $14.03 | $14.405 | $13.71 | $14.15 | 11.75M |
| Oct 2, 2026 | $14.45 | $14.75 | $13.95 | $14.215 | 11.92M |
| Oct 1, 2026 | $14.755 | $15.03 | $14.19 | $14.23 | 15.97M |
| Sep 30, 2026 | $14.65 | $15.11 | $14.10 | $14.82 | 29.34M |
| Sep 29, 2026 | $12.79 | $15.30 | $12.78 | $14.45 | 78.17M |
| Sep 28, 2026 | $10.88 | $11.165 | $10.68 | $10.99 | 12.23M |
| Sep 25, 2026 | $10.90 | $11.13 | $10.69 | $11.00 | 12.63M |
| Sep 24, 2026 | $10.40 | $10.83 | $10.15 | $10.80 | 11.93M |
| Sep 23, 2026 | $10.69 | $10.845 | $10.12 | $10.19 | 15.92M |
| Sep 22, 2026 | $10.175 | $10.80 | $10.03 | $10.64 | 16.06M |
| Sep 21, 2026 | $10.43 | $10.64 | $10.03 | $10.19 | 13.13M |
| Sep 18, 2026 | $10.12 | $10.27 | $9.83 | $10.25 | 22.88M |
| Sep 17, 2026 | $10.25 | $10.98 | $9.985 | $10.02 | 24.2M |
| Sep 16, 2026 | $9.45 | $9.925 | $9.435 | $9.87 | 19.69M |
| Sep 15, 2026 | $9.21 | $9.38 | $8.98 | $9.36 | 11.09M |
| Sep 14, 2026 | $8.56 | $9.41 | $8.54 | $9.26 | 21.04M |
| Sep 11, 2026 | $8.25 | $8.695 | $8.075 | $8.60 | 12.39M |
The latest Smart Investors Daily articles mentioning IOVA.
Company
Market Activity
Research & News
IOVA research
Company profile and research snapshot.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | Baird | Neutral | — |
| Sep 30, 2026 | Wells Fargo | Overweight | — |
| Sep 29, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 24, 2026 | Goldman Sachs | Buy | — |
| Sep 17, 2026 | Barclays | Overweight | — |
No generated briefing is available yet.
Benzinga · Oct 6, 2026
Iovance Biotherapeutics (NASDAQ:IOVA) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you
Benzinga · Oct 5, 2026
Three healthcare stocks—Quantum-Si, Kodiak Sciences and Iovance—show overbought RSI readings above 80, warning momentum-focused investors.
SeekingAlpha · Oct 5, 2026
Iovance raised 2026 revenue guidance as Amtagvi adoption accelerates with broader access, physician awareness, and faster manufacturing. Learn more about IOVA stock here.
Yahoo · Oct 4, 2026
Iovance Biotherapeutics (NASDAQ:IOVA) emerged as the top-performing mid-cap stock in the US market in the third quarter of the year, with shares soaring by 256 percent during the period, thanks to the robust demand for its cancer treatments. Much of the rally was driven by its higher growth guidance for the full year 2026, with […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IOVA.
